Welcome to our dedicated page for Tempus AI news (Ticker: TEM), a resource for investors and traders seeking the latest updates and insights on Tempus AI stock.
Tempus AI, Inc. (NASDAQ: TEM) is a healthcare technology company that applies artificial intelligence and multimodal data to precision medicine, with a strong focus on oncology and health information services. The Tempus news stream highlights how the company’s platform, genomic testing capabilities, and data-driven tools are used in collaborations, research, and commercial partnerships.
Readers can follow announcements about Tempus’s strategic collaborations with leading health systems and academic medical centers, such as multi-year precision oncology initiatives and efforts to expand access to genomic testing for cancer patients. News items also cover research partnerships with nonprofit foundations, including multi-omic studies designed to build comprehensive datasets for specific diseases like follicular lymphoma.
Tempus frequently reports on its participation in major scientific conferences, where it presents abstracts based on its de-identified multimodal database and tools like Tempus Lens. These updates include studies on tumor genomics, immune microenvironments, biomarkers, and real-world outcomes across a range of cancers, including gastrointestinal, breast, and other solid tumors. In addition, the news feed features corporate and financial updates, such as preliminary revenue results, contract value milestones, and appearances at investor conferences.
By reviewing the latest TEM news, investors and healthcare professionals can see how Tempus’s AI-enabled precision medicine solutions are being applied in clinical settings, research collaborations, and life sciences partnerships. This page is a resource for tracking ongoing developments in Tempus’s diagnostics, data and applications businesses, as well as its role in advancing data-driven approaches to cancer care and therapeutic development.
Tempus AI (NASDAQ: TEM) has announced the pricing of $650 million aggregate principal amount of 0.75% Convertible Senior Notes due 2030 in a private placement, upsized from the previously announced $400 million. The company also granted an over-allotment option for an additional $100 million in notes.
The Notes will mature on July 15, 2030, with a 0.75% annual interest rate payable semiannually. The initial conversion rate is 11.8778 shares of Class A common stock per $1,000 principal amount, equivalent to a conversion price of approximately $84.19 per share, representing a 32.5% premium to the last reported sale price.
Tempus expects net proceeds of approximately $625.3 million (or $721.7 million if the over-allotment option is exercised), which will be used to repay $274.7 million of outstanding senior secured term loans, pay $36.2 million for capped call transactions, and fund general corporate purposes. The company has entered into capped call transactions to reduce potential dilution, with an initial cap price of $111.1950, representing a 75% premium over the last reported stock price.
[ "Successful upsizing of offering from $400M to $650M indicates strong investor interest", "Low interest rate of 0.75% on the convertible notes", "Net proceeds of $625.3M (potentially $721.7M with over-allotment) strengthen balance sheet", "Capped call transactions implemented to minimize potential dilution for existing shareholders", "Debt refinancing of $274.7M in senior secured term loans could improve capital structure" ]Tempus AI (NASDAQ: TEM) has announced plans to offer $400 million in Convertible Senior Notes due 2030 through a private placement to qualified institutional buyers. The company will also grant initial purchasers an over-allotment option for an additional $60 million in notes.
The notes will be unsecured obligations maturing on July 15, 2030, with semiannual interest payments. Upon conversion, Tempus will have the flexibility to settle in cash, shares of Class A common stock, or a combination thereof. A significant portion of the proceeds will be used to repay $274.7 million in outstanding senior secured term loans.
To mitigate potential dilution, Tempus plans to enter into capped call transactions with financial institutions. These transactions are designed to reduce dilution of Class A common stock upon note conversion and/or offset cash payments exceeding the principal amount of converted notes.
Ambry Genetics, a subsidiary of Tempus AI (NASDAQ: TEM), has announced the validation of its CARE Program's accuracy in a peer-reviewed study published in the Journal of the National Comprehensive Cancer Network. The study demonstrates that CARE achieves 99.5% accuracy in interpreting NCCN Guidelines for hereditary cancer risk assessment, successfully identifying 398 out of 400 real-world patient cases.
The CARE Program is a HIPAA-compliant digital tool that integrates with electronic health records to assess patients' cancer risks through medical and family history collection. This system helps identify candidates for hereditary cancer testing and increased cancer screening, particularly important as approximately 5% of individuals have cancer predisposition gene mutations but most are unaware.
Tempus AI (NASDAQ: TEM) has announced its involvement in nearly 1,500 research projects over the past decade, demonstrating its commitment to advancing precision medicine through AI technology. The company's contributions include approximately 1,000 biopharma research projects and 500 provider-led research initiatives through its diagnostic portfolio and biological modeling capabilities.
Since its founding in 2015, Tempus has collaborated with academic institutions, health systems, and biopharma organizations, supporting over 200 projects with diagnostic assays and about 65 research initiatives through its biological modeling lab. The company's AI-powered platform provides comprehensive solutions for clinical and therapeutic research, focusing on therapy selection and drug discovery.